TrialBMC cancer2022

Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.

Yongchang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.